HC Wainwright & Co. Maintains Buy on CASI Pharmaceuticals, Lowers Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on CASI Pharmaceuticals but lowered the price target from $12 to $6.
May 15, 2024 | 3:46 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
HC Wainwright & Co. has maintained a Buy rating on CASI Pharmaceuticals but lowered the price target from $12 to $6.
The Buy rating suggests continued confidence in CASI Pharmaceuticals' long-term potential, but the lowered price target indicates a more cautious short-term outlook. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100